Terms: = Pancreatic cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Treatment
236 results:
1. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract] [Full Text] [Related]
2. Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer.
Rowell MC; Deschênes-Simard X; Lopes-Paciencia S; Le Calvé B; Kalegari P; Mignacca L; Fernandez-Ruiz A; Guillon J; Lessard F; Bourdeau V; Igelmann S; Duman AM; Stanom Y; Kottakis F; Deshpande V; Krizhanovsky V; Bardeesy N; Ferbeyre G
Cell Cycle; 2023 Oct; 22(19):2172-2193. PubMed ID: 37942963
[TBL] [Abstract] [Full Text] [Related]
3. Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer.
Briseño-Díaz P; Schnoor M; Bello-Ramirez M; Correa-Basurto J; Rojo-Domínguez A; Arregui L; Vega L; Núñez-González E; Palau-Hernández LA; Parra-Torres CG; García Córdova OM; Zepeda-Castilla E; Torices-Escalante E; Domínguez-Camacho L; Xoconostle-Cazares B; Meraz-Ríos MA; Delfín-Azuara S; Carrión-Estrada DA; Villegas-Sepúlveda N; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37813486
[TBL] [Abstract] [Full Text] [Related]
4. The inhibition of pancreatic cancer progression by k-ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
5. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
6. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S; Öztürk SC; Yanik H; Tavukcuoglu E; Şahin A; Datta D; Charisse K; Álvarez DM; Loza MI; Calvo A; Sulheim E; Loevenich S; Klinkenberg G; Schmid R; Manoharan M; Esendağlı G; Alonso MJ
J Control Release; 2023 May; 357():67-83. PubMed ID: 36921725
[TBL] [Abstract] [Full Text] [Related]
7. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive review of pancreatic cancer and its therapeutic challenges.
Jiang S; Fagman JB; Ma Y; Liu J; Vihav C; Engstrom C; Liu B; Chen C
Aging (Albany NY); 2022 Sep; 14(18):7635-7649. PubMed ID: 36173644
[TBL] [Abstract] [Full Text] [Related]
9. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in k-ras-driven cancer.
Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
[TBL] [Abstract] [Full Text] [Related]
10. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
11. Targeting G-Quadruplex DNA for cancer Chemotherapy.
Debbarma S; Acharya PC
Curr Drug Discov Technol; 2022; 19(3):e140222201110. PubMed ID: 35156574
[TBL] [Abstract] [Full Text] [Related]
12. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
[TBL] [Abstract] [Full Text] [Related]
13. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report.
Calcaterra V; Chiricosta L; Mazzon E; Gugnandolo A; Alberti D; Maestri L; Meroni M; Vestri E; Verduci E; Dilillo D; Zuccotti G; Pelizzo G
Orphanet J Rare Dis; 2021 Oct; 16(1):455. PubMed ID: 34715892
[TBL] [Abstract] [Full Text] [Related]
14. Recent Advances in pancreatic cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.
Schlick K; Kiem D; Greil R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680101
[TBL] [Abstract] [Full Text] [Related]
15. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract] [Full Text] [Related]
16. treatment Approach to Adenocarcinoma of the Ampulla of Vater.
Patel M; Uboha NV
Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
[TBL] [Abstract] [Full Text] [Related]
17. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
18. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract] [Full Text] [Related]
19. Ras sumoylation in cell signaling and transformation.
Dai W; Xie S; Chen C; Choi BH
Semin Cancer Biol; 2021 Nov; 76():301-309. PubMed ID: 33812985
[TBL] [Abstract] [Full Text] [Related]
20. Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.
Liu M; Wang D; Luo Y; Hu L; Bi Y; Ji J; Huang H; Wang G; Zhu L; Ma J; Kim E; Luo CK; Abbruzzese JL; Li X; Yang VW; Li Z; Lu W
Cell Death Dis; 2021 Feb; 12(2):189. PubMed ID: 33594044
[TBL] [Abstract] [Full Text] [Related]
[Next]
